Back to Search
MARK KOZLOFF, MD
MD
Hematology & Oncology Physician
NPI: 1134166879Individual
Specialties, Licenses & Credentials
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
01038049A(IN)IL036047581(IL)
Research & Publications (13)
Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
PMID 19649772·Invest New Drugs·2010
3-trial
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
PMID 19201650·Lancet Oncol·2009
3-trial
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
PMID 18854571·J Clin Oncol·2008
4-observational
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
PMID 18758303·J Thorac Oncol·2008
3-trial
A phase II study of ABT-751 in patients with advanced non-small cell lung cancer.
PMID 18520803·J Thorac Oncol·2008
3-trial
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.
PMID 17409864·J Thorac Oncol·2006
3-trial
Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
PMID 16615097·Cancer·2006
3-trial
Thoracoscopic application of a topical sealant for the management of persistent posttraumatic pneumothorax.
PMID 16456444·J Trauma·2006
8-other
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
PMID 16258101·J Clin Oncol·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 71 W 156TH ST, SUITE 401
HARVEY, IL 60426 - Phone
- (708) 339-4800
Quick Facts
- NPI
- 1134166879
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 13
Are you this provider?
Claim Your Profile